EGFR and non-small cell lung carcinoma: EGFR (epidermal growth factor receptor) inhibitors Erlotinib, Gefitinib and Afatinib, as well as Osimertinib, which targets the T970M mutant EGFR, have been approved for use in non-small-cell lung cancers (21).